A BLA, or Biologics License Application, is the formal submission a company files with the U.S. Food and Drug Administration to get approval to sell a biological product. It serves the same basic purpose as a New Drug Application (NDA) for conventional drugs, but it applies specifically to products derived from living sources, such as vaccines, gene therapies, and monoclonal antibodies. The application must demonstrate that the product is safe, pure, and potent before the FDA will issue a license to market it.
What a BLA Covers
A BLA is required for biological products, which differ from conventional drugs in a fundamental way: they come from living sources like human cells, animal tissues, or microorganisms rather than being chemically synthesized in a lab. This category includes vaccines, blood and blood-derived products, allergenic extracts, cellular and gene therapies, and therapeutic proteins like monoclonal antibodies. Because these products are complex and harder to characterize than small-molecule drugs, the FDA holds them to a distinct regulatory standard.
The legal authority for a BLA comes from Section 351 of the Public Health Service Act, which requires any firm manufacturing a biologic for sale in the U.S. to hold a license for that product. This is different from conventional drugs, which are approved under the Federal Food, Drug, and Cosmetic Act through the NDA process. In practice, both pathways require extensive safety and efficacy data, but a BLA places additional emphasis on manufacturing controls because even small changes in how a biologic is produced can alter the final product.
What Goes Into a BLA Submission
A BLA contains detailed information across several categories: the manufacturing process, the product’s chemistry and physical characteristics, pharmacology data, clinical pharmacology, and results from clinical trials showing the product works and is safe. The manufacturing section, often called Chemistry, Manufacturing, and Controls (CMC), is especially critical for biologics. It describes exactly how the product is made, tested, and stored, down to the specific facilities involved.
Before submitting, the manufacturer must complete process performance qualification, meaning the commercial-scale manufacturing process has been validated and shown to consistently produce a product meeting quality standards. Data from this validation phase must be included in the application itself. All manufacturing facilities must also be registered with the FDA at the time of submission and ready for inspection.
The Two BLA Pathways
There are two main routes for filing a BLA, distinguished by which section of the Public Health Service Act they fall under.
A 351(a) application is for original biological products. This is the full submission, requiring a complete package of nonclinical and clinical data proving safety, purity, and potency from scratch.
A 351(k) application is for biosimilars, products that are highly similar to an already-approved biologic (called the reference product). Instead of repeating the full development program, a biosimilar applicant must show that its product has the same mechanism of action, route of administration, dosage form, and strength as the reference product, with only minor differences in clinically inactive components. If the manufacturer wants the product designated as interchangeable (meaning pharmacists can substitute it without consulting the prescriber), it typically needs to conduct a switching study where patients alternate between the biosimilar and the reference product to confirm there’s no loss of effectiveness or increase in risk.
Who Reviews a BLA
Two FDA centers handle BLA reviews depending on the product type. The Center for Biologics Evaluation and Research (CBER) oversees blood products, vaccines, allergenic products, tissues, and cellular and gene therapies. The Center for Drug Evaluation and Research (CDER) handles most therapeutic biologics, including monoclonal antibodies and other protein-based treatments. The distinction matters mainly for the company filing, since each center has its own submission procedures and review staff, but the standards for approval are consistent.
Review Timeline and Fees
Once a BLA is submitted, the FDA has 60 days to decide whether the application is complete enough to file for review. The clock for the formal review period starts after that filing date. Under the current performance goals set by the Prescription Drug User Fee Act (PDUFA), the FDA aims to act on 90% of standard original BLA submissions within 10 months of filing. Priority reviews, granted for products that offer significant improvements over existing treatments, have a 6-month target.
Filing a BLA is expensive. For applications requiring clinical data, the user fee is approximately $4.7 million as of the most recent fee schedule. This fee funds the FDA’s review infrastructure and is separate from the annual fees manufacturers pay for each approved product and each manufacturing facility.
Facility Inspections During Review
A BLA cannot be approved without a physical inspection of every manufacturing facility listed in the application. These pre-license inspections happen during the review period, and the FDA expects to see the final commercial process actively running when inspectors arrive. The manufacturer must provide a preliminary manufacturing schedule in the submission so the FDA can plan its inspection timeline.
Inspectors verify that the facility complies with the standards described in the application and meets all applicable regulations. This is one of the reasons biologics manufacturing is so tightly controlled: the product is defined not just by its molecular structure but by the process used to make it. A facility that doesn’t match what’s described in the BLA can delay or prevent approval.
What Happens After Review
At the end of the review cycle, the FDA either approves the BLA and issues a biologics license, or sends a Complete Response Letter. A Complete Response Letter means the review cycle is finished but the application isn’t ready for approval. It outlines the specific issues the company needs to address, which could range from manufacturing deficiencies to requests for additional clinical data. The company can then resubmit with the requested changes, triggering a new review cycle.
Once approved, the license allows the company to commercially manufacture and distribute the product. Any future changes to the manufacturing process, facilities, or product characteristics require additional submissions to the FDA, with the level of regulatory scrutiny depending on how significantly the change could affect the product’s safety or effectiveness.